NSE · SUVEN · Healthcare
Suven Life Sciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2 Cr with net profit ₹-11 Cr — a -734.87% net margin, versus -479.36% the period before.
Shareholding
As of 2026-08-31
- Promoter65.47%
- Public31.32%
- FII0.48%
- DII2.73%
66,647 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.99× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #45 of 530 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Ports & Special Economic Zone Ltd. | ₹3,96,281 Cr | 119.03 | 4.12 | 13.32% | 33.06% |
| Eternal Limited | ₹3,00,898 Cr | 1641.05 | 9.25 | 1.18% | 0.67% |
| BSE Limited | ₹1,44,424 Cr | 183.25 | 21.67 | 37.42% | 51.66% |
| GAIL (India) Ltd. | ₹1,15,393 Cr | 77.65 | 1.3 | 8.51% | 5.34% |
| GMR Airports Limited | ₹1,13,720 Cr | 371.38 | — | -10.6% | 1.19% |
| Mazagon Dock Shipbuilders Ltd. | ₹93,080 Cr | 137.02 | 9.54 | 26.48% | 21.23% |
| One 97 Communications Ltd. | ₹84,640 Cr | 460.56 | 5.28 | 4.55% | 6.55% |
| Meesho Limited | ₹82,654 Cr | — | 18.7 | -28.13% | -10.75% |
| Info Edge (India) Ltd. | ₹80,881 Cr | 142.88 | 2.13 | 3.82% | 0.44% |
| Swiggy Limited | ₹79,558 Cr | — | 4.34 | -22.68% | -18.02% |
| Suven Life Sciences Ltd.(this company) | ₹8,830 Cr | — | 10.51 | -46.73% | -3881.32% |
AI analysis
AI-generated · google/gemini-2.5-flashSuven Life Sciences Ltd. is listed with a market capitalization of Rs 9565 Cr. The company reported a revenue of Rs 17.55 Cr with a profit margin of -3881.32%. Its 52-week high was Rs 371 and its 52-week low was Rs 124.11.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Promoter holding is substantial at 70.0777% as of June 30, 2026.
- +There are no reported promoter pledges.
Negatives
- −The company reported a negative profit margin of -3881.32%.
- −Revenue declined by -43.1%.
- −Return on Equity (ROE) is significantly negative at -46.73%.
- −Return on Capital Employed (ROCE) is significantly negative at -45.4184%.
- −The company is under LT-ASM (Long Term Additional Surveillance Measure) Stage 1.
Financial Performance
The company's annual revenue declined by -43.1% to Rs 17.55 Cr. Quarterly revenue for March 2026 was Rs 1.52 Cr, following Rs 2.81 Cr in December 2025 and Rs 0.92 Cr in September 2025. Net profit for March 2026 was -Rs 45.6 Cr, which was an improvement from -Rs 101.92 Cr in December 2025.
Profitability & Returns
Suven Life Sciences Ltd. reported a negative profit margin of -3881.32%. The Return on Equity (ROE) was -46.73%, and the Return on Capital Employed (ROCE) was -45.4184%. Quarterly EBITDA has been consistently negative, with -Rs 45.44 Cr in March 2026 and -Rs 101.92 Cr in December 2025.
Balance Sheet
The company maintains a debt-to-equity ratio of 0, indicating no debt. The book value per share stands at Rs 29.74. While debt-free, the negative profitability ratios suggest challenges in generating returns from existing capital.
Ownership & Pledges
As of June 30, 2026, promoters held 70.0777% of the shares, with public holding at 26.4284%. Institutional holding, including DIIs and FIIs, was 3.4939%. There were no promoter pledges reported, indicating no shares were encumbered by the promoters.
Regulatory & Surveillance
Suven Life Sciences Ltd. is currently under LT-ASM (Long Term Additional Surveillance Measure) Stage 1, a regulatory measure. This indicates the exchange has identified parameters requiring closer monitoring.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Aug 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.